Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

XBRL 30 June 2022 filed with the SEC

September 1, 2022May 23, 2023 Alterity Therapeutics

XBRL 30 June 2022 filed with the SEC

2022

Post navigation

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy

Related Posts

Prana Enrolls First Patient in the “Reach2HD” Phase II Huntington Disease Trial

July 17, 2013August 16, 2022

Alterity Therapeutics Raises $3.25 M AUD in Placement

February 23, 2024February 23, 2024

Prana receives FDA Orphan Drug Designation for PBT2 for Huntington Disease

September 8, 2014August 16, 2022

Recent Posts

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
Alterity to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065